Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR)

Biochemical Journal

Volumn 379, Issue 3, 2004, Pages 731-738

  Berrevoets, Cor A ^a   Umar, Arzu ^a   Trapman, Jan ^b   Brinkmann, Albert O ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Androgen receptor (AR) mutation; Antiandrogen; Nuclear receptor co repressor (N CoR); Transcriptional intermediary factor 2 (TIF2); Transcriptional repression

Indexed keywords

BIOCHEMISTRY; CONFORMATIONS; ORGANIC COMPOUNDS; TUMORS;

ANDROGEN RECEPTORS; LIGANDS; PROSTRATE CANCER;

ENZYMES;

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; CYPROTERONE ACETATE; ISOPROTEIN; LIGAND; METRIBOLONE; MIFEPRISTONE; PROTEIN P160;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANDROGEN ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CYPROTERONE ACETATE; DOWN-REGULATION; GENE EXPRESSION REGULATION; LIGANDS; MALE; METRIBOLONE; MICE; MIFEPRISTONE; MUTATION; NUCLEAR PROTEINS; NUCLEAR RECEPTOR COACTIVATOR 2; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

ANIMALIA;

EID: 2542638568     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20031456     Document Type: Article

References (43)

1. Keller, E. T., Ershler, W. B. and Chang, C. (1996) The androgen receptor: a mediator of diverse responses. Front. Biosci. 1, d59-d71
2. Balk, S. P. (2002) Androgen receptor as a target in androgen-independent prostate cancer. Urology 60, 132-138
3. Veldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A. and Mulder, E. (1992) Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31, 2393-2399
4. Quigley, C. A., de Bellis, A., Marschke, K. B., El-Awady, M. K., Wilson, E. M. and French, F. S. (1995) Androgen receptor defects: historical, clinical, and molecular perspectives. Endocrinol. Rev. 16, 271-321
5. Brinkmann, A. O., Blok, L. J., de Ruiter, P. E., Doesburg, P., Steketee, K., Berrevoets, C. A. and Trapman, J. (1999) Mechanisms of androgen receptor activation and function. J. Steroid Biochem. Mol. Biol. 69, 307-313
6. Heinlein, C. A., and Chang, C. (2002) The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol. Endocrinol. 16, 2181-2187
7. Robyr, D., Wolffe, A. P. and Wahli, W. (2000) Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol. Endocrinol. 14, 329-347
8. Hermanson, O., Glass, C. K. and Rosenfeld, M. G. (2002) Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol. Metab. 13, 55-60
9. Kuil, C. W. and Mulder, E. (1994) Mechanism of antiandrogen action: conformational changes of the receptor. Mol. Cell. Endocrinol. 102, R1-R5
10. Reid, P., Kantoff, P. and Oh, W. (1999) Antiandrogens in prostate cancer. Invest. New Drugs 17, 271-284
11. Kuil, C. W., Berrevoets, C. A. and Mulder, E. (1995) Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action, J. Biol. Chem. 270, 27569-27576
12. Suzuki, H., Akakura, K., Komiya, A., Aida, S., Akimoto, S. and Shimazaki, J. (1996) Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29, 153-158
13. Taplin, M. E., Bubley, G. J., Ko, Y. J., Small, E. J., Upton, M., Rajeshkumar, B. and Balk, S. P. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 59, 2511-2515
14. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C., Trapman, J., Brinkmann, A. O. and Mulder, E. (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173, 534-540
15. Shi, X. B., Ma, A. H., Xia, L., Kung, H. J. and de Vere White, R. W. (2002) Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 62, 1496-1502
16. Steketee, K., Timmerman, L., Ziel-van der Made, A. C. J., Doesburg, P., Brinkmann, A. O. and Trapman, J. (2002) Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int. J. Cancer. 100, 309-317
17. Chang, C.-Y. and McDonnel, D. P. (2002) Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol. Endocrinol. 16, 647-660
18. Jackson, T. A., Richer, J. K., Bain, D. L., Takimoto, G. S., Tung, L. and Horwitz, K. B. (1997) The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 11, 693-705
19. Smith, C. L., Nawaz, Z. and O'Malley, B. W. (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11, 657-666
20. Zhang, X., Jeyakumar, M., Petukhov, S. and Bagchi, M. K. (1998) A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol. Endocrinol. 12, 513-524
21. Alland, L., Muhle, R., Hou, H., Jr, Potes, J., Chin, L., Schreiber-Agus, N. and DePinho, R. A. (1997) Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature (London) 387, 49-55
22. Heinzel, T., Lavinsky, R. M., Mullen, T. M., Soderstrom, M., Laherty, C. D., Torchia, J., Yang, W. M., Brard, G., Ngo, S. D., Davie, J. R. et al. (1997) A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (London) 387, 43-48
23. Nagy, L., Kao, H. Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L. and Evans, R. M. (1997) Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell (Cambridge, Mass.) 89, 373-380
24. Huang, E. Y., Zhang, J., Miska, E. A., Guenther, M. G., Kouzarides, T. and Lazar, M. A. (2000) Nuclear receptor co-repressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev. 14, 45-54
25. Shang, Y., Myers, M. and Brown, M. (2002) Formation of the androgen receptor transcription complex. Mol. Cell 9, 601-610
26. Dotzlaw, H., Moehren, U., Mink, S., Cato, A. C. B., Iniguez, L. and Baniahmad, A. (2002) The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol. Endocrinol. 16, 661-673
27. Cheng, S., Brzostek, S., Lee, S. R., Hollenberg, A. N. and Balk, S. P. (2002) Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol. Endocrinol. 16, 1492-1501
28. Liao, G., Chen, L. Y., Zhang, A., Godavarthy, A., Xia, F., Ghosh, J. C., Li, H. and Chen, J. D. (2003) Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J. Biol. Chem. 278, 5052-5061
29. Horlein, A. J., Naar, A. M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., Kamei, Y., Soderstrom, M. and Glass, C. K. (1995) Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature (London) 377, 397-404
30. Brinkmann, A. O., Faber, P. W., van Rooij, H. C., Kuiper, G. G., Ris, C., Klaassen, P., van der Korput, J. A., Voorhorst, M. M., van Laar, J. H. and Mulder, E. (1989) The human androgen receptor: domain structure, genomic organization and regulation of expression. J. Steroid Biochem. 34, 307-310
31. Berrevoets, C. A., Doesburg, P., Steketee, K., Trapman, J. and Brinkmann, A. O. (1998) Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor 2). Mol. Endocrinol. 12, 1172-1183
32. Kuiper, G. G., de Ruiter, P. E., Trapman, J., Boersma, W. J., Grootegoed, J. A. and Brinkmann, A. O. (1993) Localization and hormonal stimulation of phosphorylation sites in the LNCaP-cell androgen receptor. Biochem. J. 291, 95-101
33. Zegers, N. D., Claassen, E., Neelen, C., Mulder, E., van Laar, J. H., Voorhorst, M. M., Berrevoets, C. A., Brinkmann, A. O., van der Kwast, T. H. and Ruizeveld de Winter, J. A. (1991) Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Biochim. Biophys. Acta 1073, 23-32
34. Perissi, V., Staszewski, L. M., McInerney, E. M., Kurokawa, R., Krones, A., Rose, D. W., Lambert, M. H., Milburn, M. V., Glass, C. K. and Rosenfeld, M. G. (1999) Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev. 13, 3198-3208
35. Nagy, L., Kao, H. Y., Love, J. D., Li, C., Banayo, E., Gooch, J. T., Krishna, V., Chatterjee, K., Evans, R. M. and Schwabe, J. W. (1999) Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev. 13, 3209-3216
36. Ghosh, J. C., Yang, X., Zhang, A., Lambert, M. H., Li, H., Xu, H. E. and Chen, J. D. (2002) Interactions that determine the assembly of a retinoid X receptor/corepressor complex. Proc. Natl. Acad. Sci. U.S.A. 99, 5842-5847
37. Horwitz, K. B. (1992) The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocrinol. Rev. 13, 146-163
38. Cadepond, F., Ulmann, A. and Baulieu, E. E. (1997) RU486 (milepristone): mechanisms of action and clinical uses. Annu. Rev. Med. 48, 129-156
39. Liu, Z., Auboeuf, D., Wong, J., Chen, J. D., Tsai, S. Y., Tsai, M. J. and O'Malley, B. W. (2002) Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc. Natl. Acad. Sci. U.S.A. 99, 7940-7944
40. Jepsen, K., Hermanson, O., Onami, T M., Gleiberman, A. S., Lunyak, V., McEvilly, R. J., Kurokawa, R., Kumar, V., Liu, F., Seto, E. et al. (2000) Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell (Cambridge, Mass.) 102, 753-763
41. Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S. and Wilson, E. M. (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61, 4315-4319
42. Sack, J. S., Kish, K. F., Wang, C., Attar, R. M., Kiefer, S. E., An, Y., Wu, G. Y., Scheffler, J. E., Salvati, M. E., Krystek, S. R., Jr et al. (2001) Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 98, 4904-4909
43. Massiello, D., Cheng, S., Bubley, G. J., Lu, M. L. and Balk, S. P. (2002) Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J. Biol. Chem. 277, 26321-26326